Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Name

Click to order products descending

Display 15 Products per page

Verubecestat
Read More
Verubecestat’s (Merck & Co) Phase Ib studies revealed highly impressive results in its capability to

almost abolish cerebrospinal fluid (CSF) amyloid-beta fragments.
September 2, 2016
Find out more
Vertex triple combinations
Read More
Vertex is developing several triple combination regimens in order to further its cystic fibrosis portfolio with the best such regimen, combining a new CFTR corrector compound
September 3, 2018
Find out more
Vericiguat
Read More
Vericiguat is a first-in-class soluble guanylate cyclase (sGC) stimulator that acts to increase levels of cyclic guanosine monophosphate (cGMP) via the nitric oxide-sGC-cGMP pathway.
December 11, 2017
Find out more
Venofer
Read More
Venofer (poly-nuclear iron (III)-hydroxide in sucrose; Vifor/Luitpold Pharmaceuticals) is an iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease.
January 11, 2018
Find out more
Venetoclax
Read More
Venetoclax (AbbVie/Roche) is a novel B-cell lymphoma-2 (BCL-2) inhibitor currently being developed

for treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL).
September 11, 2015
Find out more
Venclexta
Read More
Venclexta (venetoclax; AbbVie/Roche) is an inhibitor of the B-cell lymphoma-2 (BCL-2) family of proteins.
January 31, 2019
Find out more
Veliparib
Read More
Veliparib is a small-molecule poly (ADP-ribose) polymerase (PARP) inhibitor being developed by AbbVie. PARP is an enzyme that plays an essential role in DNA repair mechanisms and homologous recombination events.
February 26, 2020
Find out more
Velcade
Read More
Velcade (bortezomib; Takeda/Johnson & Johnson) is an intravenously or subcutaneously administered 26S proteasome inhibitor that affects multiple signaling cascades and induces cell death.
August 9, 2018
Find out more
Vectibix
Read More
Vectibix (panitumumab; Amgen/Takeda) is a fully human immunoglobulin G2 monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor (EGFR).
December 11, 2017
Find out more
VB-111
Read More
VB-111 (VBL Therapeutics) will be able to succeed in the US as an add-on therapy to Avastin

(bevacizumab; Genentech/Roche/Chugai) in the second-line of therapy, should it present positive data

from the Phase III GLOBE study.
April 13, 2016
Find out more
Vasotec
Read More
Vasotec’s (enalapril; Merck & Co/Valeant) role in chronic heart failure (CHF) is severely limited by

competition from generic equivalents.
August 2, 2016
Find out more
Vascepa
Read More
Vascepa (icosapent ethyl) is marketed by Amarin for the treatment of severe hypertriglyceridemia. The molecule itself is a semi-synthetic, highly purified derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA).
November 20, 2019
Find out more
Vargatef
Read More
Boehringer Ingelheim will hope to increase Vargatef’s (nintedanib) market share at second-line despite

rising competition in this setting.
August 30, 2016
Find out more
Value-Based Pricing – Evolution Rather Than Revolution

$5,000.00

A new value-based assessment (VBA) process is scheduled to come into effect in the UK in late 2014. There have been significant delays in determining how this would work in practice, reflecting VBA’s complexity.
November 4, 2016
Find out more
Valoctocogene Roxaparvovec
Read More
Valoctocogene roxaparvovec (BioMarin), also known as valrox, is an adeno-associated virus-mediated gene therapy that delivers human B domain-deleted coagulation factor VIII (fVIII) to patients with hemophilia A.
May 20, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *